Document is current
Any future updates will be listed below
-
Authors
Tarantino, Paolo
Cha, Jaeyoon
Binboga Kurt, Busem
Chu, Xiangying
Jovanović, Bojana
Zhou, Andrew
Hughes, Melissa
Russo, Douglas
DiLullo, Molly
Wrabel, Eileen
Jeselsohn, Rinath
Lin, Nancy U.
Carter, Jamie
Chen, Yisang Serenity
Li, Tianyu
Tayob, Nabihah
Mittendorf, Elizabeth A.
Schnitt, Stuart J.
Goel, Shom
Tolaney, Sara M.
-
Funding
Funding for this research was provided by:
Terri Brodeur Breast Cancer Foundation
METAvivor Early Career Investigator Award
Saverin Award
Mehlman Family Funds
Benderson Family Funds
Breast Cancer Research Foundation
Susan G. Komen
- License Information
-
More Information
Article History
Received: 14 July 2025
Accepted: 1 February 2026
First Online: 13 February 2026
Competing interests
: P.T. reports consulting fees from AstraZeneca, Daiichi Sankyo, Gilead, Genentech/Roche, Novartis, Menarini/Stemline, and Eli Lilly. NUL reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Seattle Genetics, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Stemline/Menarini, Artera Inc., Eisai, and Shorla Oncology; royalties from Up to date (book); and travel support from Olema Pharmaceuticals, AstraZeneca, and Daiichi Sankyo. SMT reports consulting or advisory roles for Novartis, Pfizer/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Bristol Myers Squibb/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Johnson&Johnson/Ambrx, Launch Therapeutics, Zuellig Pharma, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summit Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals, Tempus, and Boundless Bio; institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep, Daiichi Sankyo, Menarini/Stemline, Jazz Pharmaceuticals, and Olema Pharmaceuticals; and travel support from Eli Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, and Roche.
